Genopsys has developed a proprietary evolution method called idsPCR™ / SCRAM™ - a novel technology that allows for the random introduction of structural changes at any position in a protein. It optimizes proteins for a wide range of applications, including medical research, therapies and advanced biomaterials. In combination with high-throughput screening capabilities, this process yields proteins with significantly improved performance characteristics and broad patent protection. Genopsys libraries deliver a more diverse collection of variant proteins with improved functional properties than traditional directed evolution technologies. idsPCR™ / SCRAM™ makes the protein optimization process tunable, rapid and cost-effective. By commercializing novel biomolecules, our technology promises to transform the way disease is detected, treated, and managed in cancer and disorders of the central nervous system. The company’s short-term goal is to rapidly validate and leverage idsPCR™ / SCRAM™ technologies by developing enzyme-based detection molecules to address the growing multi-billion dollar market in personalized medicine.